Developed By Clinicians for Clinicians
The MultiPath® platform is designed to address the growing problem of antibiotic drug-resistance. By determining the appropriate antibiotic treatment in hours, versus days, the MultiPath platform will help medical professionals avoid prescribing an inappropriate or overly broad antibiotic.
Don Straus, Chief Scientific Officer and Founder of First Light Diagnostics discusses the MultiPath platform.
UTI Research
Studies have shown that individuals make 7 to 10.5 million office visits per year for urinary tract infection (UTI) symptoms1. These visits create a societal cost of approximately $3.5 Billion per year in the US.
Timing is Critical
Based on independent research, 60% of clinicians wait more than 3 days for UTI ID/AST results. Without timely results from current tests, medical professionals must use their experience to determine the correct antibiotic to treat an infection. This often means prescribing a broad-spectrum antibiotic, creating additional risk of new infections such as C.Diff.
Personal Impacts of Empirical Therapy
In a one-month window, 92% of outpatient respondents surveyed had to change therapy. When an ineffective antibiotic has been selected, the infection can worsen, creating more discomfort for the patient. In addition, return visits to the office generate additional co-pays and time from work, school, etc.
MultiPath will Change Targeted Therapy for the Better
The MultiPath platform will be able to take a sample directly from a specimen to determine the pathogen in 30 minutes and identify the targeted therapy in about 4 hours. These rapid, targeted results will significantly reduce the use of broad-spectrum antimicrobials to treat UTI.